5 Case Studies of Progesterone Treatment for Menopause





Progesterone treatment provides a balanced approach to menopause medication, particularly when estrogen therapy is involved. It is proven that estrogen alone thickens lining, which increases the risk of endometrial cancer. 


Progesterone treatment case studies highlight the capacity of progesterone HRT in treating some menopause symptoms. Also, it provides valuable information about its practical application and individual responses to progesterone in menopause treatment.

1. Hot Flashes and Night Sweats

A randomized controlled trial that lasted 12 weeks had 133 healthy postmenopausal women aged 44 to 62 years. They were 1 to 10 years after their final menstruation. Participants were administered 300 mg of oral micronized progesterone daily at bedtime.

The mean daily VMS (vasomotor symptoms) score decreased by 10.0 points in the progesterone group compared to a 4.4-point reduction in the placebo group. This showed that oral micronized progesterone effectively reduced the severity and frequency of hot flashes and night sweats in the participants.

A PROGEST trial study proved the efficacy of oral micronized progesterone (in different doses)  in treating moderate to severe VMS in postmenopausal women. The prospective, multi-center, randomized, double-blind, and placebo-controlled trial had 74 women who were assigned to receive 200 mg, 300 mg, or 400 mg of progesterone daily, or a placebo for 12 weeks.

A moderate to severe hot flashes reduction by:
  • 7.7 episodes per day with 200 mg
  • 8.3 episodes per day with 300 mg
  • 9.0 episodes per day with 400 mg
  • 7.4 episodes per day in the placebo group
2. Low Sex Drive

A comprehensive systematic review and meta-analysis published in Menopause in 2023 analyzed data from 47 randomized controlled trials involving 35,912 participants. They are perimenopausal and postmenopausal women focusing on estrogen alone or combined with progestogens (synthetic progesterone) treatment.

Results showed that estrogen therapy alone had a standardized mean difference (SMD) of 0.16 (95% CI, 0.02 to 0.2), a small benefit in improving sexual function. 

The addition of progestogens didn’t show improvement, with an SMD of 0.11 (95% CI, −0.07 to 0.29). Thus, estrogen therapy offers slight improvements in sexual function and progestogen’s efficacy remains uncertain.

Another study published in Climacteric in 2011 assessed the effects of different hormone treatments on early postmenopausal women's sexual function.

It involved 48 participants randomized to receive either dehydroepiandrosterone (DHEA), hormone replacement therapy (HRT) with estradiol plus dydrogesterone (synthetic progesterone), or tibolone over a 12-month period.

The results indicated that women receiving DHEA or HRT had improvements in sexual function compared to baseline as measured by the McCoy Female Sexuality Questionnaire.

3. Heart Health

A study published in the Journal of Clinical Endocrinology and Metabolism evaluated the effects of progesterone therapy on cardiovascular health in postmenopausal women. It's a 3-month randomized and placebo-controlled trial in healthy and early postmenopausal women.

It included 133 healthy postmenopausal women who were randomized to receive either 300 mg of oral micronized progesterone daily or a placebo for three months.

Progesterone had neutral effects on body weight, waist circumference, blood pressure, resting heart rate, total cholesterol, low-density lipoprotein cholesterol, triglycerides, fasting glucose, inflammation markers, and coagulation markers.

However, there was a decrease in high-density lipoprotein cholesterol (HDL-C) levels in the progesterone group compared to the placebo group. 

Researchers noted short-term progesterone therapy has a neutral impact on cardiovascular health in healthy postmenopausal women because the overall Framingham General Cardiovascular Risk Profile remained low and unchanged.

4. Hair and Skin

A prospective, randomized, double-blind, and placebo-controlled study on 40 non-hysterectomized postmenopausal women's skin elasticity, hydration, thickness, and surface lipids.

They were randomized to receive either a combination of 2 mg 17β-estradiol and 10 mg dydrogesterone (Femoston) or a placebo over seven 28-day cycles for seven months.

The HRT group showed skin elasticity and hydration improvement, particularly at the right upper arm's inner side.

Also, skin thickness improves the skin's suppleness compared to the placebo group. Skin surface lipids remain neutral. Researchers noted these HRT types and dosage lessen postmenopausal women's skin aging.

5. Endometrial Cancer Risk

A systematic review published in Best Practice and Research Clinical Endocrinology and Metabolism analyzed 84 randomized controlled trials (RCTs). It assessed the efficacy of various progestogens (including progesterone) in preventing endometrial hyperplasia and malignancy in postmenopausal women undergoing menopause hormone therapy (MHT).

The studies reviewed varied in duration and participant numbers. The findings suggest that most progestogens (when used in appropriate doses and regimens) are effective in protecting the endometrium during MHT.









 

Location: 4RRR5QPX+63

Comments

Post a Comment

Popular posts from this blog

7 Progesterone Benefits for Menopause

Image
  Progesterone is a natural hormone from the ovaries. It’s important in the menstrual cycle, pregnancy, uterus, and breast development.  It’s prescribed as part of hormone replacement therapy (HRT) for menopausal women (particularly those who still have their uterus). It's used to prevent endometrial hyperplasia (a thickening of the uterine lining) that  occurs when taking estrogen alone. On average, it’s prescribed in combination with estrogen (either continuously (every day) or cyclically like 12-14 days per month). Women take this for irregular periods, endometriosis or luteal phase support in fertility treatment and it’s available in:  Pills Injections Intrauterine device (IUD) Vaginal gel Patch applied to the skin Foods that have zinc, vitamin C, vitamin B, and magnesium Oral micronized progesterone pill is the most popular as it's the most familiar for most people. Progesterone for Menopause Taking progesterone in a hormone replacement treatment plan makes me...
Read more

Increased Sex Drive during Menopause

Image
15%-20% of menopausal women report an increase in libido. Midlife women with increased emotional awareness and good communication skills can express well their sexual desires toward their partners. Testosterone therapy boosts menopausal women’s libido by addressing hormonal imbalances that contribute to decreased sexual desire. While 40%-50% of menopausal women complain of decrease in sex drive, about 15%-20% report an increase in libido. This surge comes from hormonal changes, particularly the relative balance of testosterone, which become more noticeable as estrogen and progesterone levels decline. Also, some women experience increased vaginal lubrication during estrogen surges. This makes intercourse more comfortable and enhances libido. Furthermore, psychological and emotional factors contribute to its rise. Here are the detailed explanation: Psychosocial Factors Decreased caretaking responsibilities and lower chances of getting pregnant give women more time to focus on intimate r...
Read more

5 Causes of Vaginal Bleeding on HRT

Image
  60% of menopausal women on HRT (no matter the type) experience vaginal bleeding. depends on the type of HRT a woman is taking: If you're taking sequential HRT (estrogen daily and progesterone for part of the month), you'll likely experience withdrawal bleeding at the end of the progesterone cycle (similar to a period), lasting 3-7 days. Sequential HRT is recommended during perimenopause or in the first 2 years after menopause. This bleeding (withdrawal bleeding) is lighter than a typical menstrual period. This therapy has a scheduled bleeding and it’s ideal for women who want to take control of their period. With continuous combined HRT (estrogen and progesterone daily), bleeding is less common as some women experience spotting or light bleeding in the first few months. This treatment is recommended 1 or 2 years after menopause. Some women switched from sequential HRT to continuous HRT because of less bleeding. On average, vaginal bleeding or spotting starts after the first...
Read more